Introduction: organ involvement in the cardiometabolic syndrome
- PMID: 17675904
- DOI: 10.1111/j.0197-3118.2006.05454.x
Introduction: organ involvement in the cardiometabolic syndrome
Abstract
The cardiometabolic syndrome is a construct associated with an increased risk of type 2 diabetes mellitus, cardiovascular disease (coronary artery disease, peripheral arterial disease, and stroke), chronic kidney disease, and the metabolic hepatopathy referred to as nonalcoholic fatty liver disease or nonalcoholic steatohepatitis. Thus, the term cardiometabolic syndrome includes all of these metabolic, islet, cardiovascular, renal, and hepatic disorders and clustering clinical syndromes. This overview of the cardiometabolic syndrome is designed to review the clinical complications and the end-organ cellular and extracellular matrix remodeling events that occur with the cardiometabolic syndrome. The MINER acronym will serve as an outline, representing: Myocardial and metabolic-hepatopathy, Intimal and islet, Neurovascular, Endothelial, and Renal oxidation-reduction (redox) stress and remodeling.
Similar articles
-
Nonalcoholic steatohepatitis and the cardiometabolic syndrome.J Cardiometab Syndr. 2006 Winter;1(1):36-40. doi: 10.1111/j.0197-3118.2006.05523.x. J Cardiometab Syndr. 2006. PMID: 17675901
-
Cardiometabolic syndrome and chronic kidney disease: what is the link?J Cardiometab Syndr. 2006 Winter;1(1):58-65. doi: 10.1111/j.0197-3118.2006.05470.x. J Cardiometab Syndr. 2006. PMID: 17675896 Review.
-
The cardiometabolic syndrome and liver disease.J Cardiometab Syndr. 2008 Winter;3(1):5-6. doi: 10.1111/j.1559-4572.2008.08248.x. J Cardiometab Syndr. 2008. PMID: 18326973 No abstract available.
-
Myocardial myocyte remodeling and fibrosis in the cardiometabolic syndrome.J Cardiometab Syndr. 2006 Fall;1(5):326-33. doi: 10.1111/j.1559-4564.2006.05626.x. J Cardiometab Syndr. 2006. PMID: 17679785 Review.
-
Eicosanoids and renal damage in cardiometabolic syndrome.Expert Opin Drug Metab Toxicol. 2008 Feb;4(2):165-74. doi: 10.1517/17425255.4.2.165. Expert Opin Drug Metab Toxicol. 2008. PMID: 18248310 Free PMC article. Review.
Cited by
-
Interactions of the advanced glycation end product inhibitor pyridoxamine and the antioxidant alpha-lipoic acid on insulin resistance in the obese Zucker rat.Metabolism. 2008 Oct;57(10):1465-72. doi: 10.1016/j.metabol.2008.05.018. Metabolism. 2008. PMID: 18803954 Free PMC article.
-
Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome.J Am Soc Hypertens. 2008 Jul-Aug;2(4):239-66. doi: 10.1016/j.jash.2007.12.002. Epub 2008 Jun 2. J Am Soc Hypertens. 2008. PMID: 20409906 Free PMC article.
-
Calcific uremic arteriolopathy: pathophysiology, reactive oxygen species and therapeutic approaches.Oxid Med Cell Longev. 2010 Mar-Apr;3(2):109-21. doi: 10.4161/oxim.3.2.11354. Oxid Med Cell Longev. 2010. PMID: 20716935 Free PMC article. Review.
-
Ultrastructure of islet microcirculation, pericytes and the islet exocrine interface in the HIP rat model of diabetes.Exp Biol Med (Maywood). 2008 Sep;233(9):1109-23. doi: 10.3181/0709-RM-251. Epub 2008 Jul 18. Exp Biol Med (Maywood). 2008. PMID: 18641056 Free PMC article.
-
Metabolic interactions of AGE inhibitor pyridoxamine and antioxidant alpha-lipoic acid following 22 weeks of treatment in obese Zucker rats.Life Sci. 2009 Apr 10;84(15-16):563-8. doi: 10.1016/j.lfs.2009.01.021. Epub 2009 Feb 11. Life Sci. 2009. PMID: 19302804 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical